semaglutide mash fda approval Semaglutide, a GLP-1R agonist, is also effective for patients – MedNess FDA Approves Semaglutide for MASH

Having a lot of fat in the belly means that it can also accumulate in the organs of that area, such as the heart and liver as well as the muscle tissue

Nutrients 16 (19), 3305

ESPEN guidelines indicate that any patient with active inflammation who is being treated with sulfalazine or who has macrocytosis should be routinely monitored for serum folic acid and red blood cell levels

Additionally, healthcare providers should monitor their patients for signs of cancer while taking semaglutide

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials